세계의 약물유전체학 기술 시장 : 시장 규모, 점유율 및 동향 분석(치료 영역별, 기술별, 지역별), 부문별 예측(2025-2030년)

Pharmacogenomics Technology Market Size, Share & Trends Analysis Report By Therapeutic Area (Neurological Disorders, Cardiovascular Disease), By Technology (PCR, In-situ Hybridization), By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,521,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950 ￦ 9,953,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950 ￦ 12,818,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

한글목차

세계의 약물유전체학 기술 시장 성장과 동향 :

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 약물유전체학 기술 시장은 2030년까지 123억 8,000만 달러에 달할 것으로 예측되며, 2025년부터 2030년까지 연평균 복합 성장률(CAGR) 8.1%로 확대될 것으로 예측되고 있습니다.

진단학은 약물유전체학 검사의 대두에 적응하고 있으며, 이어서 새로운 생물학적 치료가 추가되어 있습니다. 이러한 위험 검사 예측, 환자 계층화 및 치료 반응 모니터링과 같은 이러한 검사의 사용과 관련된 이점은 기존 방법에 비해 이 약물유전체학 동반진단 시장의 중요한 진보의 원천이 될 것으로 예측됩니다.

또한, 약물유전체학 검사 제품은 환자의 치료 요법을 개별화하고 최적화하는 데 의사를 지원합니다.

그러나 약물유전체학에 기초한 검사를 의약품 개발 스케줄에 조기에 통합하고 동시에 승인을 얻기 위한 과제가 존재하는 것이 성장의 방해가 될 것으로 예측됩니다.

약물유전체학 기술 시장 : 분석 개요

• 암 영역이 2024년에 40% 가까운 점유율을 차지해 치료 분야 부문을 지배했습니다.
• 프레시젼 종양의 연구자는 복수의 약제를 여러가지 조합해 사용해, 종양의 성장을 단순히 늦추는 것이 아니라, 종양을 소멸시키는 것을 목표로 하고 있습니다.
• 테라노스틱스의 기술에 관해서는 중합효소 연쇄반응(PCR)이 시장을 독점하고 있습니다.
• 북미가 약물유전체학 기술 시장을 독점하고 있는 것은 의약품 개발자가 자사 제품을 진단약과 조합하기 위한 경제적 인센티브가 있기 때문입니다.
• 아시아태평양은 기업이 미개척 사업 기회를 획득하기 위해 노력하고 있기 때문에 예측 기간 중에 가장 빠른 성장을 보일 것으로 예측되고 있습니다.
• 약물유전체학 기술 시장에서 사업을 전개하는 주요 기업은 QIAGEN, GE HealthCare, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd., FOUNDATION MEDICINE, INC., Oxford Nanopore Technologies plc., Twist Bioscience, Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc., Abbott 등이 있습니다.
• FOUNDATION MEDICINE, INC.는 2024년 11월 미국 식품의약국(FDA)이 FoundationOne Liquid CDx를 TEPMETKO(에르로티닙)에 의한 치료 대상인 비소세포폐암(NSCLC)에서 MET 엑손 14 스킵의 변화를 가진 환자를 동정하기 위한 파트너 진단약으로 승인했다고 발표했습니다.

목차

제1장 분석 방법 및 범위

제2장 주요 요약

제3장 약물유전체학 기술 시장 : 변동 요인, 경향, 범위

• 시장 연관 전망
  • 상위 시장 전망
  • 관련/부수 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 약물유전체학 기술 시장 : 분석 툴
  • 업계 분석 : Porter's Five Forces 분석
  • PESTEL 분석

제4장 약물유전체학 기술 시장 : 치료 영역별 추정 및 동향 분석

• 치료 영역별 대시보드
• 약물유전체학 기술 시장 : 치료 영역별 변동 분석
• 세계의 약물유전체학 기술 시장 : 시장 규모의 예측과 동향 분석, 치료 영역별(2018-2030년)
• 종양
  • 시장의 추정 및 예측(2018-2030년)
  • 폐암
  • 유방암
  • 대장암
  • 자궁경부암
  • 기타
• 신경질환
  • 시장의 추정 및 예측(2018-2030년)
• 심혈관 질환
  • 시장의 추정 및 예측(2018-2030년)
• 면역 질환
  • 시장의 추정 및 예측(2018-2030년)
• 감염증
  • 시장의 추정 및 예측(2018-2030년)
• 기타
  • 시장의 추정 및 예측(2018-2030년)

제5장 약물유전체학 기술 시장 : 기술별 추정 및 동향 분석

• 기술별 대시보드
• 약물유전체학 기술 시장 : 기술별 변동 분석
• 세계의 약물유전체학 기술 시장 : 시장 규모의 예측과 동향 분석, 기술별(2018-2030년)
• PCR
• in situ 하이브리드화
• 면역조직화학
• 시퀀싱
• 기타

제6장 약물유전체학 기술 시장 : 지역별 추정 및 동향 분석

• 시장 대시보드 : 지역별
• 시장 점유율 분석 : 지역별(2024년 및 2030년)
• 약물유전체학 기술 시장 : 주요 포인트, 지역별
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 노르웨이
  • 스웨덴
  • 덴마크
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 태국
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제7장 경쟁 구도

• 최근 동향과 영향 분석 : 주요 시장 진출기업별
• 기업/경쟁의 분류
• 벤더 상황
  • 주요 기업의 히트맵 분석(2024년)
• 기업 프로파일
  • QIAGEN
  • GE HealthCare
  • Agilent Technologies, Inc.
  • F. Hoffmann-La Roche Ltd
  • FOUNDATION MEDICINE, INC
  • Thermo Fisher Scientific Inc.
  • Oxford Nanopore Technologies plc.
  • Twist Bioscience
  • Leica Biosystems Nussloch GmBH
  • Pfizer Inc
  • Abbott

JHS

영문 목차

영문목차

Pharmacogenomics Technology Market Growth & Trends:

The global pharmacogenomics technology market is anticipated to reach USD 12.38 billion by 2030 and is anticipated to expand at a CAGR of 8.1% from 2025 to 2030, according to a new report by Grand View Research, Inc. Diagnostics is adapting to the rise of pharmacogenomic tests, which are followed by the addition of new biological treatments. These tests enable cost-effective treatment and also add value to the process of drug development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to a significant source of progress in this pharmacogenomics companion diagnostics market.

In addition, pharmacogenomics testing products aid physicians in individualizing and optimization of the patient's therapeutic regimen. Pharmacogenomics and theranostics are paving the way for integrated medicine. Rapid evolution in this group of specialized molecular diagnostic tests is contributing to improvement for the assessment of real-time treatment of disease.

However, the presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development timelines for gaining approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy have become a necessary attribute for the success of theranostics.

Pharmacogenomics Technology Market Report Highlights:

• Oncology dominated the therapeutic area segment with nearly 40% share in 2024, driven by the presence of a substantial number of products
• Precision oncology researchers aim to use multiple medications in various combinations to eliminate tumors rather than merely slowing their growth
• Polymerase Chain Reaction (PCR) dominated the market the with respect to technology for theranostics. The PCR technique is widely used in clinical diagnostics due to its numerous advantages, making it a key method in the field.
• North American region dominates the pharmacogenomics technology market because of economic incentives for drug developers to pair their products with diagnostics
• Asia Pacific market is projected to showcase the fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
• Key players operating in the pharmacogenomics technology market include QIAGEN; GE HealthCare.; Agilent Technologies, Inc.; F. Hoffmann-La Roche Ltd; FOUNDATION MEDICINE, INC.; Oxford Nanopore Technologies plc.; Twist Bioscience.; Thermo Fisher Scientific Inc.; Leica Biosystems Nussloch GmBH; Pfizer Inc.; Abbott
• In November 2024, FOUNDATION MEDICINE, INC. announced that the U.S. Food and Drug Administration (FDA) had approved FoundationOne Liquid CDx as a partner diagnostic to identify patients with MET exon 14 skipping alterations in non-small cell lung cancer (NSCLC) eligible for treatment with TEPMETKO(erlotinib). This blood-based test helps guide targeted therapy decisions, supporting precision oncology through pharmacogenomic profiling.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Therapeutic area
  • 1.2.2. Technology
  • 1.2.3. Regional Scope
  • 1.2.4. Estimates and Forecasts Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Therapeutic area outlook
  • 2.2.2. Technology outlook
  • 2.2.3. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Pharmacogenomics Technology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
  • 3.2.2. Market restraint analysis
• 3.3. Pharmacogenomics Technology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape

Chapter 4. Pharmacogenomics Technology: Therapeutic Area Estimates & Trend Analysis

• 4.1. Therapeutic Area Dashboard
• 4.2. Pharmacogenomics Technology Market: Therapeutic Area Movement Analysis
• 4.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
• 4.4. Oncology
  • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. Lung Cancer
    • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Breast Cancer
    • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. Colorectal Cancer
    • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. Cervical Cancer
    • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.6. Others
    • 4.4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.5. Neurological Disorders
  • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.6. Cardiovascular Disorders
  • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.7. Immunological Disorders
  • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.8. Infectious Diseases
  • 4.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 4.9. Others
  • 4.9.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Pharmacogenomics Technology Market: Technology Estimates & Trend Analysis

• 5.1. Technology Segment Dashboard
• 5.2. Pharmacogenomics Technology Market: Technology Movement Analysis
• 5.3. Global Pharmacogenomics Technology Market Size & Trend Analysis, by Technology, 2018 to 2030 (USD Million)
• 5.4. PCR
  • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.5. In-situ Hybridization
  • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.6. Immunohistochemistry
  • 5.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.7. Sequencing
  • 5.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
• 5.8. Others
  • 5.8.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Pharmacogenomics Technology Market: Regional Estimates & Trend Analysis

• 6.1. Regional Market Dashboard
• 6.2. Regional Market Share Analysis, 2024 & 2030
• 6.3. Pharmacogenomics Technology Market by Region: Key Takeaways
• 6.4. North America
  • 6.4.1. U.S.
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.2. Canada
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4.3. Mexico
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Europe
  • 6.5.1. UK
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Germany
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. France
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.4. Italy
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.5. Spain
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.6. Norway
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.7. Sweden
    • 6.5.7.1. Key country dynamics
    • 6.5.7.2. Regulatory framework/ reimbursement structure
    • 6.5.7.3. Competitive scenario
    • 6.5.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.8. Denmark
    • 6.5.8.1. Key country dynamics
    • 6.5.8.2. Regulatory framework/ reimbursement structure
    • 6.5.8.3. Competitive scenario
    • 6.5.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Asia Pacific
  • 6.6.1. Japan
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.2. China
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.3. India
    • 6.6.3.1. Key country dynamics
    • 6.6.3.2. Regulatory framework/ reimbursement structure
    • 6.6.3.3. Competitive scenario
    • 6.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.4. Australia
    • 6.6.4.1. Key country dynamics
    • 6.6.4.2. Regulatory framework/ reimbursement structure
    • 6.6.4.3. Competitive scenario
    • 6.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.5. South Korea
    • 6.6.5.1. Key country dynamics
    • 6.6.5.2. Regulatory framework/ reimbursement structure
    • 6.6.5.3. Competitive scenario
    • 6.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6.6. Thailand
    • 6.6.6.1. Key country dynamics
    • 6.6.6.2. Regulatory framework/ reimbursement structure
    • 6.6.6.3. Competitive scenario
    • 6.6.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 6.7. Latin America
  • 6.7.1. Brazil
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7.2. Argentina
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 6.8. MEA
  • 6.8.1. South Africa
    • 6.8.1.1. Key country dynamics
    • 6.8.1.2. Regulatory framework/ reimbursement structure
    • 6.8.1.3. Competitive scenario
    • 6.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.2. Saudi Arabia
    • 6.8.2.1. Key country dynamics
    • 6.8.2.2. Regulatory framework/ reimbursement structure
    • 6.8.2.3. Competitive scenario
    • 6.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.3. UAE
    • 6.8.3.1. Key country dynamics
    • 6.8.3.2. Regulatory framework/ reimbursement structure
    • 6.8.3.3. Competitive scenario
    • 6.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8.4. Kuwait
    • 6.8.4.1. Key country dynamics
    • 6.8.4.2. Regulatory framework/ reimbursement structure
    • 6.8.4.3. Competitive scenario
    • 6.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments & Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. Key company heat map analysis, 2024
• 7.4. Company Profiles
  • 7.4.1. QIAGEN
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. GE HealthCare
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Agilent Technologies, Inc.
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. F. Hoffmann-La Roche Ltd
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. FOUNDATION MEDICINE, INC
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Thermo Fisher Scientific Inc.
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. Oxford Nanopore Technologies plc.
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Twist Bioscience
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Leica Biosystems Nussloch GmBH
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. Pfizer Inc
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives
  • 7.4.11. Abbott
    • 7.4.11.1. Company overview
    • 7.4.11.2. Financial performance
    • 7.4.11.3. Product benchmarking
    • 7.4.11.4. Strategic initiatives

관련자료